Clinical-stage biotech company Vigil Neuroscience announced that Sanofi made a strategic investment of 40 million US dollars in the company at a converted price of $7.44 per share. After the announcement, Vigil Neuroscience rose by 58% in pre-market trading.
赛诺菲安万特战略投资临床阶段生物技术公司
Sanofi's global strategy involves investing in clinical-stage biotechnology companies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.